Uncategorized

MaaT Pharma reported that the U.S. Food and Drug Administration has lifted the clinical hold and cleared the Investigational New Drug application to initiate in the U.S. an open-label, single arm Phase 3 pivotal clinical trial evaluating the safety and efficacy of MaaT013 to treat gastrointestinal acute Graft-versus-Host Disease as a third line of treatment.

Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, is pleased to announce it will host a symposium at the 3rd ISIET’s International Symposium on Inner Ear Therapeutics, an event sponsored by Sensorion, taking place on April 28-30, 2023, in Marrakech, Morocco.

Belief BioMed Group announced the completion of patient dosing in its Phase III Registrational Clinical Trial of BBM-H901, a gene therapy for Hemophilia B developed and manufactured in-house by Shanghai Belief-Delivery Biomed Co., Ltd., its wholly owned subsidiary.

Bridge Biotherapeutics announced that it received notice from the U.S. Food and Drug Administration that it may proceed with the first-in-human study of BBT-207, which has the potential to be a mutant selective and broad-spectrum fourth-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor for the treatment of non-small cell lung cancer.

This week, the FDA will release its verdict on Biogen and Ionis’ ALS candidate tofersen and three other investigational medicines for psychiatric disorders, hormonal insufficiency and gut infection.

Los pacientes ingresados en unidades de cuidados intensivos a menudo reciben transfusiones de sangre, pero cada vez hay más pruebas de posibles daños así como de beneficios.

Revisión sobre patogénesis, epidemiología, clínica y vacunación de dengue.

The acquisition, which would be Boston Scientific’s largest in recent history, would add to the company’s cardiac portfolio.

Generative AI has roared onto the tech scene through the large language model backing ChatGPT. Companies are already deploying the algorithms in hospitals. Should healthcare be taking a pause?

Cancer vaccines enjoyed a moment in the spotlight at AACR as Moderna, Merck, Nykode Therapeutics and Transgene shared promising updates.